Randomized phase 2 trial of NP001–a novel immune regulator: Safety and early efficacy in ALS
OBJECTIVE:To assess the safety, tolerability, and preliminary efficacy of NP001, a novel immune regulator of inflammatory monocytes/macrophages, for slowing progression of amyotrophic lateral sclerosis (ALS). METHODS:This was a phase 2 randomized, double-blind, placebo-controlled trial of NP001 in 1...
Gespeichert in:
Veröffentlicht in: | Neurology : neuroimmunology & neuroinflammation 2015-06, Vol.2 (3), p.e100-e100 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Schreiben Sie den ersten Kommentar!